Ganetespib showed activity in KRAS-mutant NSCLC as monotherapy and in combinations
Wednesday, January 11, 2012 - 05:30
in Health & Medicine
The investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene. The drug was even more active when combined with traditional lung cancer treatments and other investigational targeted therapies, according to preclinical study data.